SOUTH SAN FRANCISCO, Calif. (AP) _ Veracyte Inc. (VCYT) on Tuesday reported a loss of $730,000 in its third quarter.
On a per-share basis, the South San Francisco, California-based company said it had a loss of 2 cents.
The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 7 cents per share.
The molecular diagnostic company posted revenue of $31 million in the period, also surpassing Street forecasts. Three analysts surveyed by Zacks expected $30.4 million.
Veracyte expects full-year revenue in the range of $119 million to $122 million.
Veracyte shares have more than doubled since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $26.21, more than doubling in the last 12 months.